Cargando…

Selective cell death of latently HIV-infected CD4(+) T cells mediated by autosis inducing nanopeptides

Despite significant advances in the treatment of human immunodeficiency virus type-1 (HIV) infection, antiretroviral therapy only suppresses viral replication but is unable to eliminate infection. Thus, discontinuation of antiretrovirals results in viral reactivation and disease progression. A major...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Gang, Luk, Brian T., Wei, Xiaoli, Campbell, Grant R., Fang, Ronnie H., Zhang, Liangfang, Spector, Stephen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541658/
https://www.ncbi.nlm.nih.gov/pubmed/31142734
http://dx.doi.org/10.1038/s41419-019-1661-7
Descripción
Sumario:Despite significant advances in the treatment of human immunodeficiency virus type-1 (HIV) infection, antiretroviral therapy only suppresses viral replication but is unable to eliminate infection. Thus, discontinuation of antiretrovirals results in viral reactivation and disease progression. A major reservoir of HIV latent infection resides in resting central memory CD4(+) T cells (T(CM)) that escape clearance by current therapeutic regimens and will require novel strategies for elimination. Here, we evaluated the therapeutic potential of autophagy-inducing peptides, Tat-Beclin 1 and Tat-vFLIP-α2, which can induce a novel Na(+)/K(+)-ATPase dependent form of cell death (autosis), to kill latently HIV-infected T(CM) while preventing virologic rebound. In this study, we encapsulated autophagy inducing peptides into biodegradable lipid-coated hybrid PLGA (poly lactic-co-glycolic acid) nanoparticles for controlled intracellular delivery. A single dose of nanopeptides was found to eliminate latent HIV infection in an in vitro primary model of HIV latency and ex vivo using resting CD4(+) T cells obtained from peripheral blood mononuclear cells of HIV-infected patients on antiretroviral with fully suppressed virus for greater than 12 months. Notably, increased LC3B lipidation, SQSTM1/p62 degradation and Na(+)/K(+)-ATPase activity characteristic of autosis, were detected in nanopeptide treated latently HIV-infected cells compared to untreated uninfected or infected cells. Nanopeptide-induced cell death could be reversed by knockdown of autophagy proteins, ATG5 and ATG7, and inhibition or knockdown of Na(+)/K(+)-ATPase. Importantly, viral rebound was not detected following the induction of the Na(+)/K(+)-ATPase dependent form of cell death induced by the Tat-Beclin 1 and Tat-vFLIP-α2 nanopeptides. These findings provide a novel strategy to eradicate HIV latently infected resting memory CD4(+) T cells, the major reservoir of HIV latency, through the induction of Na(+)/K(+)-ATPase dependent autophagy, while preventing reactivation of virus and new infection of uninfected bystander cells.